BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. - Wikidata - wikimedia - TriplyDB

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34245983

about

Regulatory roles of the tumor necrosis factor receptor BCMA.Clinical associations of serum interleukin-17 in systemic lupus erythematosus.BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice B Cell in Autoimmune Diseases.Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation.Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases.B cell encounters with apoptotic cells.B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice.BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo.Association of BAFF -871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients.Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus.The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease.B cells regulate thymic CD8+T cell differentiation in lupus-prone mice.Anti‑IL‑39 (IL‑23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus‑like mice.BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis.Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population.

P2860

Q30422814-CD75DFE2-2219-4F2A-9DD6-33D2BF227AE9 Q34365880-40199873-9ED0-47D8-840D-6BDD0D5E103D Q34656412-3DBAE677-71DF-4616-97CF-CC73384E48F5 Q35858608-450D08AE-056A-43E7-97C2-906BBAF05054 Q36260857-1270963C-663A-4952-BFFE-C7BD3B59E2DF Q36954468-7DA1BD55-52AC-433A-8096-80CA5585F391 Q37364008-8567EB10-2C27-478C-87B0-BBB62048C909 Q38061970-9E3E9B1B-B366-4EEA-82C2-FE0CDEEBB0B4 Q38065216-3006B0E5-6B04-459A-B196-370C5DEACD1C Q38131034-FD17A944-F6B2-4CC6-8B51-75A91C9BFE0B Q38346284-D201D04B-1BB5-4ED7-BE44-B79A2841BD6E Q38704093-11A539C6-1D39-4645-AD13-1D701E180214 Q38758838-17D75FD5-7908-459B-AAA7-C7BFC3FFEF10 Q38882580-04B56EDE-2E93-4BC9-9640-4E2775A3FD32 Q38884955-4E907C67-0ADB-449E-9CB1-AF381523D262 Q39388669-7E5E6241-B295-4182-BEBA-15B94127223B Q40401297-134B0D24-C8DD-481D-AF99-36D5CC5043A8 Q40707363-DA0B284C-C591-489F-B931-6A05ADF5AA62 Q45295655-CA0F2632-F86C-4B0B-870A-DDBEC68D2720 Q47401182-B3EF2094-CD4C-4D96-A04F-8CDA5C576700 Q48195816-6BF62D08-0263-4AC4-99F8-F6619400B421 Q48593567-D9771CD0-4CD0-485B-A085-BCA3AE37380E

P2860

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34245983

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@ast

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@en

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@nl

type

label

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@ast

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@en

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@nl

prefLabel

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@ast

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@en

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@nl

P1433

Q34245983-A249EB7A-DD30-49B3-8DAE-F1ACA101C18B

P1476

Q34245983-21E605B7-9344-4A0D-93EB-9840F473D52A

P2093

Q34245983-6EE82C12-26D3-4B8C-AE7A-36954CEC4DC9

Q34245983-91D8D401-7529-4336-95AD-A088867E59CB

Q34245983-96229EC3-F0BA-4957-BCE8-E3578D43F358

P2860

Q34245983-07516358-43EB-4559-92CC-4FCB593FA782

Q34245983-08CAF121-C714-4FF3-B165-A16F41B719B4

Q34245983-09656F1B-CD34-4DDC-B394-8ECB53114A1D

Q34245983-0B9AEA3E-B417-4D90-A0DD-5089DBE76161

Q34245983-0E7D8198-C667-4FBA-B57C-0B9359FCE2CB

Q34245983-105DB51D-A062-4AD9-BE11-43BD8499E44E

Q34245983-1409FA3C-1ECA-4855-AF22-875A010175DB

Q34245983-1429B3FD-B1B5-4CF2-A3DF-DC304108C5E2

Q34245983-1480F321-758C-4F92-A498-D2529028E98B

Q34245983-1510EA0F-7EA0-456B-B558-42A5FD77F9C1

P2888

Q34245983-35F5D33B-C6FA-4023-8095-C108C8274295

P304

Q34245983-67E14E15-93B1-45B9-84DE-AE83D967F84D

P31

Q34245983-DE003115-AFBF-4F0B-85D7-028EF6DE35C3

P356

Q34245983-D713F100-834D-43D3-AC7E-1A14CC6E682F

P407

Q34245983-4FB57127-62B3-4C79-9A96-44E3AD594309

P433

Q34245983-27E1A0F0-DF68-4AF8-8CD4-EE709DA92327

P478

Q34245983-B797CA56-9C43-4369-95EC-F166245D913E

P577

Q34245983-8758E418-7D63-4974-9CE1-48CA9454614B

P6179

Q34245983-052312C9-41EB-462E-881A-AA566A608CB2

P698

Q34245983-E090F118-E73B-4920-89C6-0699DDF7D26D

P356

P1433

Immunology & Cell Biology

P1476

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

@en

P2093

Eric F Morand

http://www.w3.org/2001/XMLSchema#string

Fabien B Vincent

http://www.w3.org/2001/XMLSchema#string

Fabienne Mackay

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

P2888

P304

293-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ICB.2011.111

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038156569

http://www.w3.org/2001/XMLSchema#string

P698

22231653

http://www.w3.org/2001/XMLSchema#string